View Older Stories View More Recent Stories
-
Form SC 13D/A Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio
-
Form SC 13G BRIGHT MINDS BIOSCIENCES Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hyku Biosciences Appoints John Gustofson to its Board of Directors
-
Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors
-
Avalo Therapuetics (AVTX) Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
-
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
-
Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases
-
Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors
-
Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates (ADCs) for solid tumours
-
Form SC 13G GLYCOMIMETICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Ensysce Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Eledon Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Biopharma Announces Upcoming Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
-
Form SC 13D Septerna, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Bright Minds Biosciences (DRUG) Closes US$35 Million Non-Brokered Private Placement
-
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
-
Form SC 13G Monopar Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Elektrofi Announces Oversubscribed $112.25 Million Series C Financing to Establish Commercial-Scale GMP Manufacturing Capacity & Accelerate Clinical Development Across its Growing Portfolio of Par
-
Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases
-
Aerovate Therapeutics (AVTE) and Jade Biosciences Announce Merger Agreement
-
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
-
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
-
Eledon Pharmaceuticals (ELDN) Prices $85M Offering at $3.65/sh
-
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Monopar Therapeutics (MNPR) Prices $19.2M Share Offering at $16.25/sh
-
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
-
AbbVie (ABBV) Acquires Aliada Therapeutics
-
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
-
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals
-
Form SC 13D/A Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Janux Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Bio Announces $82 Million Financing and Transition to Clinical Stage Company
-
Dignify Therapeutics Selected as a Praxis SCI Accelerate Company
-
Dignify to highlight recent accomplishments at the 2024 BIO Investor Forum
-
Dignify Therapeutics welcomes leading healthcare entrepreneurs Howard Palefsky and Neil Kurtz, MD to its Board of Directors
-
Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients With Metastatic and/or Unresectabl
-
Form SC 13G BioAge Labs, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Dignify Therapeutics to Participate in the BIO Investor Forum, October 2024
-
Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia
-
Superluminal Medicines Announces Formation of Scientific Advisory Board
-
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer
-
AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED SERIES B FINANCING TO FURTHER ADVANCE ITS PROPRIETARY RADIOPHARMACEUTICAL PIPELINE
-
Form SC 13D Bicara Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cidara Therapeutics (CDTX) Announces Scientific Advisory Board with Infectious Disease Experts
-
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
-
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of Directors
-
Dignify Therapeutics awarded two new research grants from the National Institutes of Health (NIH)
-
RA Capital Launches Structured Capital Solutions
